Naurex Inc. is a clinical-stage private company developing novel therapies to address unmet needs in psychiatry and neurology based on a new mechanism of action for modulating the NMDA receptor in a safe way. Naurex's lead product GLYX-13 has shown promising antidepressant activity with excellent safety in a Phase II trial, confirming the efficacy signals and safety observed in Phase I and preclinical studies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/17/12 | $38,000,000 | Series B |
Adams Street Partners Baxter Ventures Druid Bioventures Genesys Capital Latterell Venture Partners Lundbeck Northwestern University PathoCapital Savitr Capital Shire Strategic Investment Group Takeda Ventures | undisclosed |
| 12/03/14 | $80,000,000 | Series C |
Adams Street Partners Baxter Ventures Cowen Investments Druid Bioventures EcoR1 Capital Genesys Capital Goudy Park Capital H. Lundbeck A/S Latterell Venture Partners PathoCapital Portola Capital Partners Sabby Capital | undisclosed |
